Prognostic Biomarkers Market Growth, Forecast and Value Chain 2017-2027

Prognostic Biomarkers Market Value Share, Analysis and Segments 2017-2027 March 2017

About Future Market Insights Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends. We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC. Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and Retail. We have a global presence with delivery centers across India specializing in providing global research reports and country research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India. We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for our client.

Research Capabilities    

Customized Research Syndicated Research Investment Research

Social Media Research

Customized Research Syndicated Research Investment Research Social Media Research

Sector Coverage    

Automotive and Transportation Electronics, Semiconductor, and ICT Retail and Consumer Products Industrial Automation and Equipment

   

Chemicals & Materials Food and Beverages Services and Utilities Energy, Mining, Oil, and Gas

Subscription Information

For detailed subscription information please contact Hari. T (Sr. Manager - Global Business Development) T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268 Email: hari.t@futuremarketinsights.com

2

Research Methodology (1/2) Systematic Research Approach 1 Market profiling

2 Formulating discussion guide

3 Developing list of respondents

4

In-depth secondary research is used to ascertain overall market size, top industry players, top products, industry associations, etc. PMR formulates a detailed discussion guide to conduct expert and industry interviews PMR develops a list of industry players (manufacturers), distributors, retailers and industry experts

Data collection

PMR conducts interviews with industry experts, industry players, distributors and retailers

Data validation

Data is validated by triangulation method, wherein secondary, primary and PMR analysis contribute to the final data

5 6

Data analysis

Insights

7

Data is scrutinized using MS-Excel to obtain qualitative and quantitative insights about the industry PMR delivers industry insights and information in the required format (PDF)

Data Collection

   

Research & Intelligence

Data Filter & Analysis

Identifying key opinion leaders Questionnaire design In-depth interviews Coverage across value chain

Actionable Insights

A Primary Research

     

B SOLUTION     

Market participants Key strengths Product portfolio Mapping as per value chain Key focus segments

Primary Research #    

Linkedin Zoominfo Salesforce Avention

Business Solution

Desk Research

C

Key industry experts Channel study Developments Market dynamics Products Conclusions

Company Analysis

Secondary Research #    

Company websites Company annual reports White papers Financial reports

Paid Publications#    

Factiva GBI Genios Meltwater

# includes sources of databases

3

Prognostic Biomarkers Market Prognostic Biomarkers are the type of biomarkers that track the progression of a disease with or without treatment. They assess the aggressiveness of the disease and calculate the risk of recurrence or median survival for particular type of malignancy. According to an article published in Journal of Clinical and Cellular Immunology, the field of biomarkers has expanded dramatically in the last 5-6 years with the advancement in high throughput technologies such as mass spectroscopy, genomic and proteomic arrays, sequencing, and many more. Intensifying research in this field can be seen from the increase in the number of publications for novel prognostic biomarkers especially in the field of cancer. A new research presented at Association for the Study of Diabetes (EASD) 2016 Annual Meeting suggests the combination of prognostic biomarkers which could be helpful in noninvasive screening for pancreatic carcinoma in patients with new-onset diabetes. According to an article published in Ebiomedicine, recently researchers have identified 788 potential biomarkers in blood that could be used to develop an early stage carcinoma screening test for the general population. Novel drug efficiency in clinical trials on a certain population is determined using prognostic biomarkers. Hence, prognostic biomarkers have remarkable potential to affect the success rate of clinical trials. They also help in assessing the need and strategy of treatment for specific patients. In the era of personalized medicines and advanced cancer therapeutics, prognostic markers provide the precise selection of treatment for a patient. Thus, helps in reducing the side effects of chemotherapeutic drugs. For the further prediction and development of novel prognostic biomarkers, collaboration of statistical and bioinformatics data is also required. Request For Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-3139 ÂŠ2015 Future Market Insights, All Rights Reserved

4

Prognostic Biomarkers Market Prognostic Biomarkers Market: Drivers & Restraints An ideal biomarker should have analytical validity, clinical validity and clinical utility. Hence, fast, accurate and feasible prognostic biomarker will grow the demand of industry. Also, not all the patients respond favorably to drugs so continuous need of prognostic biomarkers is there for regular assessment of the treatment. Furthermore, increased development of prognostic biomarkers will reduce the treatment cost. Increasing awareness among doctors, patients and technicians in the developing countries would help in promoting the growth of market. Insufficient partnership between industry and academia is one of the restraint of the industry. More chances of experimental failure, some ethical issues, huge investment, time consumption, technical and commercial challenges limits further development of prognostic biomarkers.

Prognostic Biomarkers Market: Segmentation Segmentation by Therapeutic Type  Oncology

5

Prognostic Biomarkers Market Segmentation by End User  Research Institutes  Diagnostic labs  Pharmaceutical Industry  Academic Institutions Segmentation by Application  Drug discovery and research  Clinical Trials  Company Diagnostics  Treatment Analysis Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-3139 ©2015 Future Market Insights, All Rights Reserved

6

Prognostic Biomarkers Market Prognostic Biomarkers Market: Overview Currently, clinicians monitor treatment response by means of blood pressure measurements, antidouble-stranded DNA antibody levels, serum complement levels, urinary protein/creatinine ratios, urinary sediment, and surrogates of renal function. Unfortunately, prediction of disease progression is difficult by using these traditional biomarkers because of their little sensitivity and high LN heterogeneity at presentation. Therefore, continuous need of prognostic biomarker increases for effective treatment strategy these days. Prognostic biomarkers also help the pharmaceutical industry to develop more effective drug and reduce the chances of failure. Sensitivity, specificity and cost are some of the factors determining growth of the industry. The market demand of prognostic biomarkers will increase because of the factors like increasing population, increase in number of chronic diseases, increased investment in healthcare and many more. Long term investments is one of the requirement essential for the novel systems and thus promoting growth of the industry. One of the commercialized prognostic biomarker assay kit is the Oncotype DX which determine the likelihood that breast cancer will come back in a patient after initial treatment. Similar research activity include Komen funded research projects on prognostic biomarkers which have investment of around $ 60 million in over 120 research grants.

7

Prognostic Biomarkers Market Prognostic Biomarkers Market: Region-wise Outlook North America dominates the global market because of increasing aging population and increasing innovation and technology. According to WHO cancer trends worldwide, North America is at the top followed by Europe. Furthermore, good reimbursement scenario in these countries increase the demand. Asia-pacific region market is expected to grow in the future because of increase in the number of contract research, increasing population and per capita income of people in these countries. Development of novel biomarkers and their increasing use also help in cutting down the healthcare cost thus promoting the growth of the industry. Browse Full Report@ http://www.futuremarketinsights.com/reports/prognostic-biomarkers-market

Prognostic Biomarkers Market: Key Players Some of the key players in the prognostic biomarkers industry include Roche diagnostics, Qiagen, Johnson and Johnson, GE Healthcare, Siemens Healthcare, Merck & Co. Inc. and many others.

8

To know more about us, please visit our website:

www.futuremarketinsights.com For sales queries or new topics email us on:

sales@futuremarketinsights.com For media queries, contact the press office at press@futuremarketinsights.com For other queries contact:

Harish Tiwari (General Manager & Global Head Business Development) Future Market Insights: 3rd Floor, 207 Regent Street, London W1B 3HH T: +44 20 7692 8790 | D: +44 20 3287 4268 Email: hari.t@futuremarketinsights.com

Thank You Future Market Insights Global & Consulting Private Limited (FMI)

9

Turn static files into dynamic content formats.

Create a flipbook